<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04875754</url>
  </required_header>
  <id_info>
    <org_study_id>ICM 20-1001</org_study_id>
    <nct_id>NCT04875754</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety, Tolerability, and Range of Biologically Active Doses of ICM-203 in Mild to Moderate Knee Osteoarthritis</brief_title>
  <official_title>A Phase 1/2a, Double-Blind, Placebo-Controlled Single Dose Escalation Study of Intra-Articular ICM 203 in Subjects With Kellgren-Lawrence Grade 2 or Grade 3 Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ICM Biotech Australia Pty Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ICM Co. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability, and activity of&#xD;
      increasing doses of ICM-203 injected into the knee of subjects with mild to moderate knee&#xD;
      osteoarthritis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Group 1: ICM-203 6x10e12 vg or Placebo&#xD;
Group 2: ICM-203 2x10e13 vg or Placebo&#xD;
Group 3: ICM-203 6x10e13 vg or Placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events following administration of study drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Severity of Treatment-Emergent Adverse Events graded according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0, following administration of study drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Knee pain</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Evaluation of change from baseline in knee pain as measured using a Numerical Rating Scale (NRS) ranging from 0 (no pain) to 10 (worst pain imaginable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee function</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Evaluation of change from baseline in knee function as measured using the Function in Daily Living subscore of the Knee Injury and Osteoarthritis Outcome Score (KOOS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Articular cartilage grade</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Evaluation of change from baseline in articular cartilage grade as measured using MRI Osteoarthritis Knee Score (MOAKS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Joint space width</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Evaluation of change from baseline in Joint space width in mm as measured on knee radiograph</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Humoral response to AAV5.2 capsid</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Evaluation of change from baseline in neutralizing antibody titers against AAV5.2 in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cellular immune response to AAV5.2 capsid</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Evaluation of change from baseline in T-cell responses to AAV5.2 capsid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic biodistribution of ICM-203</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Evaluation of presence of ICM-203 in peripheral blood after administration of study drug</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Group 1: ICM-203 (Low dose) vs Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 subjects will be randomized to receive a single intra-articular injection of ICM-203 at 6x10e12 vg (n=6) or placebo (n=2) into the target knee at Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: ICM-203 (Medium dose) vs Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 subjects will be randomized to receive a single intra-articular injection of ICM-203 at 2x10e13 vg (n=6) or placebo (n=2) into the target knee at Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: ICM-203 (High dose) vs Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 subjects will be randomized to receive a single intra-articular injection of ICM-203 at 6x10e13 vg (n=6) or placebo (n=2) into the target knee at Day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>ICM-203</intervention_name>
    <description>Intra-articular injection</description>
    <arm_group_label>Group 1: ICM-203 (Low dose) vs Placebo</arm_group_label>
    <arm_group_label>Group 2: ICM-203 (Medium dose) vs Placebo</arm_group_label>
    <arm_group_label>Group 3: ICM-203 (High dose) vs Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (saline solution)</intervention_name>
    <description>Intra-articular injection</description>
    <arm_group_label>Group 1: ICM-203 (Low dose) vs Placebo</arm_group_label>
    <arm_group_label>Group 2: ICM-203 (Medium dose) vs Placebo</arm_group_label>
    <arm_group_label>Group 3: ICM-203 (High dose) vs Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. BMI of 18.0 to 40.0 kg/m2, inclusive, at the time of screening.&#xD;
&#xD;
          2. Kellgren-Lawrence grade 2 or grade 3 OA of target knee.&#xD;
&#xD;
          3. Target knee pain between 4 and 9, inclusive, on an NRS ranging from 0 (no pain) to 10&#xD;
             (worst pain imaginable).&#xD;
&#xD;
          4. KOOS function in daily living score &gt;25, a measure of knee function ranging from 0&#xD;
             (extreme problems) to 100 (no problems).&#xD;
&#xD;
          5. A stable treatment regimen for symptomatic relief of OA, including NSAIDs, for 4 weeks&#xD;
             prior to screening.&#xD;
&#xD;
          6. Female subjects of child-bearing potential, with a fertile male sexual partner, must&#xD;
             use a highly effective method of contraception (oral contraceptive, intra-uterine&#xD;
             device, or hormonal patch, injectable, or implantable device) in conjunction with a&#xD;
             male condom from screening until 52 weeks after dosing.&#xD;
&#xD;
               1. True abstinence from sexual intercourse, in accordance with the preferred and&#xD;
                  usual lifestyle of the subject, is acceptable. Periodic abstinence or avoiding&#xD;
                  sexual intercourse on days while the subject is fertile (calendar, symptothermal,&#xD;
                  post-ovulation methods), withdrawal (coitus interruptus), are not acceptable&#xD;
                  methods of contraception.&#xD;
&#xD;
               2. Non-childbearing potential is defined as postmenopausal as documented by an&#xD;
                  elevated follicle stimulating hormone level or surgical sterility (e.g., tubal&#xD;
                  ligation, hysterectomy, and/or bilateral salpingo-oophorectomy).&#xD;
&#xD;
          7. Male subjects must either be surgically sterile (vasectomy) or agree to use a male&#xD;
             condom during sexual intercourse from screening until 52 weeks after dosing; if the&#xD;
             female sexual partner is of child-bearing potential, she must also use a medically&#xD;
             acceptable form of birth control (e.g., oral contraceptive).&#xD;
&#xD;
          8. Male subjects must agree not to donate sperm from screening until 52 weeks after&#xD;
             dosing.&#xD;
&#xD;
          9. All subjects must agree not to donate blood from screening until 52 weeks after&#xD;
             dosing.&#xD;
&#xD;
         10. Able to read and understand the requirements of the study unaided and to provide&#xD;
             written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of rheumatoid arthritis, psoriatic arthritis, gout, pseudogout, autoimmune OA,&#xD;
             chondrocalcinosis, hemochromatosis, villonodular synovitis, and synovial&#xD;
             chondromatosis or other disorder that in the opinion of the Investigator could cause&#xD;
             inflammation of the knee.&#xD;
&#xD;
          2. Use of anticoagulants or known coagulopathy.&#xD;
&#xD;
          3. Influenza, COVID-19, or other vaccination less than 30 days prior to day 1.&#xD;
&#xD;
          4. Immunosuppressive therapy, including oral (but not inhaled or topical)&#xD;
             corticosteroids, less than 90 days prior to day 1.&#xD;
&#xD;
          5. Chronic narcotic use.&#xD;
&#xD;
          6. Injection of steroid, hyaluronate or other agent, into the target knee less than 90&#xD;
             days prior to day 1.&#xD;
&#xD;
          7. Receipt of an investigational product within 90 days prior to day 1.&#xD;
&#xD;
          8. Prior receipt of a gene therapy or stem cell product.&#xD;
&#xD;
          9. Major injury to the target knee, such as torn ligament or severe sprain, within 12&#xD;
             months of screening.&#xD;
&#xD;
         10. Target knee effusion &gt;2+ based on the stroke test.&#xD;
&#xD;
         11. Target knee joint space width &lt; 1 mm on knee radiograph.&#xD;
&#xD;
         12. Valgus or varus alignment of the target knee &gt;10 degrees on knee radiograph.&#xD;
&#xD;
         13. Dermatologic lesions on target knee within one month of screening.&#xD;
&#xD;
         14. Severe hip OA ipsilateral to the target knee.&#xD;
&#xD;
         15. Inability to complete study assessments, including self-administered questionnaires.&#xD;
&#xD;
         16. Disability so severe that the subject cannot comply with the study requirements,&#xD;
             including knee symptoms that result in significant difficulty or inability to walk.&#xD;
&#xD;
         17. Previous cartilage repair procedures.&#xD;
&#xD;
         18. Surgery on the target knee within 180 days prior to day 1&#xD;
&#xD;
         19. Total knee arthroplasty or other knee surgery planned in the next 12 months.&#xD;
&#xD;
         20. Donation or loss of more than 100 mL of blood within 60 days prior to day 1.&#xD;
&#xD;
         21. Pregnancy or breast-feeding, either at the time of screening or planned in the next 12&#xD;
             months.&#xD;
&#xD;
         22. Fracture or tumor on MRI of target joint.&#xD;
&#xD;
         23. Any contraindication to MRI, e.g., pacemaker, claustrophobia.&#xD;
&#xD;
         24. Any of the following laboratory values: hemoglobin &lt;8.5 gm/dL, white blood cell count&#xD;
             &lt;3500 per mm3 or &gt;15,000 per mm3, platelet count &lt;100,000/uL, creatinine &gt;2 mg/dL,&#xD;
             bilirubin &gt;2 mg/dL, aspartate aminotransferase or alanine aminotransferase &gt;2 times&#xD;
             the upper limit of normal, or international normalized ratio &gt;1.2.&#xD;
&#xD;
         25. Known HIV infection, acute or chronic, uncured hepatitis C infection, or known&#xD;
             positive serologic test for hepatitis B surface antigen.&#xD;
&#xD;
         26. Active joint infection or other concurrent medical or psychiatric condition that, in&#xD;
             the opinion of the Investigator, would make the subject unsuitable for the study.&#xD;
&#xD;
               1. Examples of medical conditions include but are not limited to: severe liver or&#xD;
                  kidney disease, uncompensated congestive heart failure, myocardial infarction&#xD;
                  within six months, unstable angina, uncontrolled hypertension, severe pulmonary&#xD;
                  disease or uncontrolled asthma, immunosuppressive disorders, history of cancer&#xD;
                  (other than cutaneous basal and squamous cell carcinoma) with less than five&#xD;
                  years documentation of a disease-free state, and poorly-controlled diabetes with&#xD;
                  Hemoglobin A1c &gt; 8.0% at screening.&#xD;
&#xD;
               2. Examples of psychiatric conditions include but are not limited to: severe&#xD;
                  depression, suicidal ideation and drug or alcohol abuse within the past year.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alison Heald, MD</last_name>
    <role>Study Director</role>
    <affiliation>ICM Co. Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alison Heald, MD</last_name>
    <phone>+1 (206) 465-3912</phone>
    <email>consulting@alisonheald.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yanghee Kim, MPH</last_name>
    <phone>+822-324-8550</phone>
    <email>yanghee.kim@icm-bio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Metro South Hospital and Health Service via the Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Kate Campbell, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kate Campbell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barwon Health</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Richard Page, MD</last_name>
    </contact>
    <investigator>
      <last_name>Richard Page, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 26, 2021</study_first_submitted>
  <study_first_submitted_qc>May 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2021</study_first_posted>
  <last_update_submitted>September 5, 2021</last_update_submitted>
  <last_update_submitted_qc>September 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adeno-associated virus</keyword>
  <keyword>gene therapy</keyword>
  <keyword>ICM-203</keyword>
  <keyword>osteoarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

